The stock of Intec Pharma Ltd. (NASDAQ:NTEC) is now priced at $0.3 and the shares are 0.01 points up or 2.81% higher compared to its previous closing price of $0.29. The stock had 1.176 million contracts set over the past session. NTEC shares’ daily volume is compared to its average trading volume at 9.546 million shares. However, it has a float of 60.13 million and although its performance was 2.92% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the NTEC share price recently placing at $0.2919 to $0.306. However, some brokerage firms have priced the stock below the average, including one that has called $0.5.
The shorts are running away from the Intec Pharma Ltd. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the NTEC shares have declined. Short interest in the stock represents just 6.85% of its float, but the volume has dropped by -809695. The volume of shorted shares dropped to 4.116 million from 4.926 million shares over the last two weeks. The average intraday trading volume has been 8.962 million shares, which means that days to cover moved to roughly 1.
In the last trading session, Intec Pharma Ltd. (NASDAQ:NTEC) raised by $0.0085 over the week and lost -$0.1187 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $1.56. The stock recorded its established 52-week high on 09/17/19.
Since 03/18/20, the stock has traded to a low of $0.1324 at 126.57%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge.
Looking at current readings, Intec Pharma Ltd.’s two-week RSI is 41.37. This suggests that the stock is neutral at the moment and that NTEC shares’ price movement remains stable. The stochastic readings are equally revealing at 15.62% meaning the NTEC share price is currently in overbought territory.
The technical chart shows that the NTEC stock will likely settle at between $0.3067 and $0.3134 per share. However, if the stock dips below $0.2926, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.2852.
Currently, the stock is trading in the red of MACD, with a reading of -0.0007. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at ROTH Capital cut their recommendation for NTEC from Buy to Neutral in October 11 review while maintai their target price of $10 to $1. Maxim Group analysts see the stock as a Buy, but they also dropped the share’s target price from $8 to $12 in a flash note released to investors on March 26. Ladenburg Thalmann analysts see the stock as Buy when the analysts initiated the share price coverage on February 28.
The average rating for the NTEC equity is 3 and is currently gathering a bullish momentum. Of 4 analysts tracking Intec Pharma Ltd. polled by Reuters, 4 rated NTEC as a hold. The remaining 0 analysts were split evenly. However, the split wasn’t equal as a majority (0) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.